HHS purchases IV antiviral drug to treat monkeypox
The Department of Health and Human Services this week purchased $26 million worth of intravenous TPOXX (tecovirimat) to treat monkeypox, which the manufacturer expects to deliver next year. Under its contract with SIGA Technologies, HHS may still purchase additional oral and IV TPOXX, an antiviral drug approved by the Food and Drug Administration to treat smallpox and available under an investigational protocol to treat monkeypox. TPOXX is available free to states and territories through the Strategic National Stockpile, which held over 1.7 million treatment courses before the monkeypox outbreak. HHS last week declared the U.S. outbreak, which exceeds 10,000 cases, a public health emergency.
Related News Articles
Headline
The Administration for Strategic Preparedness and Response June 25 announced a flu pandemic preparedness and response strategy in response to the threat of…
Headline
The Centers for Disease Control and Prevention June 25 issued a Health Alert Network Health Advisory about an increased risk of dengue virus infections in the…
Headline
The Food and Drug Administration last week granted enforcement discretion for the use of conjunctival swabs by laboratories as part of human testing for H5N1…
Headline
The Centers for Disease Control and Prevention May 21 announced recommendations that flu surveillance systems continue operating at enhanced levels during the…
Headline
Pediatric sepsis is "an aggressive and unrelenting adversary that knows neither geographic nor demographic bounds," writes Chris DeRienzo, M.D., AHA’s senior…
Headline
Centers for Disease Control and Prevention and state and territorial public health officials Friday met to discuss preparedness planning for bird flu after one…